Scarica l'app Stockscreener
16.93
2.76%
-0.48
Dopo l'orario di chiusura:
16.93
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$17.41
Aprire:
$17.37
Volume 24 ore:
3.42M
Relative Volume:
1.39
Capitalizzazione di mercato:
$2.13B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-8.3399
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
-2.92%
1M Prestazione:
-7.03%
6M Prestazione:
-50.10%
1 anno Prestazione:
-58.45%
Intervallo 1D:
$16.69
$17.37
Intervallo di 1 settimana:
$16.61
$17.71
Portata 52W:
$16.10
$43.76
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
16.93 | 2.19B | 715.22M | -250.10M | -205.58M | -2.03 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Apellis Pharmaceuticals Insiders Sell US$3.1m Of Stock, Possibly Signalling Caution - simplywall.st
(APLS) Long Term Investment Analysis - news.stocktradersdaily.com
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
Citigroup Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts - Benzinga
APLS: Citigroup Lowers Price Target for Apellis Pharmaceuticals - GuruFocus
APLS: Citigroup Lowers Price Target for Apellis Pharmaceuticals | APLS Stock News - GuruFocus
Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Grow - GuruFocus
How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com
Apellis Pharmaceuticals Stock: Have Some Patience (NASDAQ:APLS) - Seeking Alpha
Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Mizuho Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $20.00 - Defense World
Northern Trust Corp Has $17.46 Million Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Sets New 12-Month Low Following Analyst Downgrade - Defense World
Mizuho Lowers Price Target for Apellis Pharmaceuticals (APLS) | - GuruFocus
Apellis (APLS) Faces Price Target Cut as Challenges Persist | AP - GuruFocus
Transcript : Apellis Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Mizuho Securities Adjusts Apellis Pharmaceuticals Price Target to $20 From $30, Maintains Neutral Rating - marketscreener.com
Cantor Fitzgerald Has Negative View of APLS FY2025 Earnings - Defense World
Wedbush Cuts Earnings Estimates for Apellis Pharmaceuticals - Defense World
HC Wainwright Has Negative Estimate for APLS Q2 Earnings - Defense World
William Blair Issues Pessimistic Forecast for APLS Earnings - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Rating Lowered to Outperform at Raymond James - Defense World
What is HC Wainwright’s Forecast for APLS Q1 Earnings? - Defense World
Apellis Pharmaceuticals Stumbles Over Funding And Sales Hurdles - Finimize
Wells Fargo & Company MN Sells 133,752 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Scotiabank Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Robert W. Baird Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
APLS: Apellis Pharmaceuticals Stock Downgraded by B of A Securit - GuruFocus
B of A Securities Downgrades Apellis Pharmaceuticals (BIT:1APLS) - Nasdaq
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Pri - GuruFocus
Sector Update: Health Care - marketscreener.com
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Price Target Cut | APLS Stock News - GuruFocus
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down - MSN
Apellis Pharmaceuticals downgraded by Raymond James due to ’added uncertainty’ - Investing.com Canada
Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back? - Insider Monkey
BofA Adjusts Apellis (APLS) Rating to Neutral, Lowers Price Targ - GuruFocus
Apellis (APLS) Faces Downgrade Amid Sales Volatility Concerns | - GuruFocus
Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers - simplywall.st
BofA Adjusts Apellis (APLS) Rating to Neutral, Lowers Price Target | APLS Stock News - GuruFocus
First Trust Advisors LP Has $818,000 Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say - MSN
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates - MSN
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Apellis Pharmaceuticals (APLS) Analyst Rating Update by RBC Capi - GuruFocus
Apellis Pharmaceuticals (APLS) Analyst Rating Update by RBC Capital | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS) Price Target Lowered by Scotiaban - GuruFocus
Apellis (APLS) Price Target Reduced by Scotiabank Analyst | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS): Wells Fargo Lowers Price Target to $26 | APLS Stock News - GuruFocus
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):